Zylox-Tonbridge Delivers Strong First-Half 2026 Results as International Revenue Surges 349%

Zylox-Tonbridge reported 1H 2026 results with revenue up 31.1% YoY to RMB 632 million and net profit up 47.8% YoY to RMB 179 million, with gross margin of 73.4% and net margin of 28.3%. International revenue surged 349.3% YoY to RMB 70.64 million (11.2% of total), supported by faster commercialization across 70 countries and an April acquisition of a 60% stake in Germany’s optimed. NMPA approved 11 additional products in China during the period, while the company continues portfolio and channel expansion in Europe, Germany/France, Latin America, and Asia-Pacific.

Analysis

The main signal is not the reported growth itself; it is that CHYL is starting to look like a self-funded international platform rather than a purely China/VBP-driven franchise. Direct sales in Western Europe matter because they convert gross margin into a more durable asset: less distributor leakage, better pricing control, and more visibility on repeat orders. If this mix shift sticks, the market can justify a higher revenue multiple even if domestic pricing stays capped.

Second-order, the pressure is likely to show up first in lower-tier peripheral and neurovascular niches where buyers are most price-sensitive. European incumbents and distributors can absorb some share loss, but the real spillover is margin compression in the channel, not necessarily immediate unit-share collapse. The optimed acquisition also creates a potential manufacturing/supply-chain advantage: if CHYL can localize assembly and logistics in Europe, it reduces tariff and lead-time friction and makes its low-price position harder to dislodge.

The contrarian risk is that this is still a low base story: triple-digit international growth can decelerate fast once the first distributor fills. The key falsifier is whether 2H shows recurring direct orders and whether gross margin holds near the current level after Europe shipping, integration, and SG&A are fully absorbed. If growth cools while expenses rise, the stock should rerate back to a domestic medtech multiple rather than a global growth premium.

Key Decisions for Investors

• Initiate a small tactical long CHYL on weakness over the next 1-2 weeks; use a 3-6 month horizon and size for liquidity risk. Upside is a re-rating if international mix remains >10% and direct sales recur; thesis breaks if 2H growth drops sharply or gross margin slips below ~72%.
• Relative-value idea: long CHYL / short IHI as a hedge-adjusted expression of 'emerging-market low-cost export medtech wins share.' This works only if Europe/EMEA traction proves repeatable; cover if CHYL's international revenue normalizes back toward low double digits.
• Do not chase the first print. Wait for a post-earnings consolidation or pullback before adding, since the growth base is small and the market may overpay for one-off tender wins. If the stock holds gains for 2-3 weeks without volume fading, that is the stronger confirmation signal.
• Set a catalyst watch on Germany/France order follow-through into the next quarter. Repeated direct sales orders there would be the first clean evidence that CHYL is taking share from incumbent European device vendors rather than just booking initial channel fill.